GRCL: Bathi resik saben saham (EPS TTM) Gracell Biotechnologies Ltd

Logo perusahaan publik Gracell Bio (GRCL)

Gracell Biotechnologies (GRCL) aims for global leadership in CAR-T therapy for blood cancer through the expansion of clinical trials. The rolling earnings per share indicator demonstrates profit dynamics, where the value -1.01 captures the metric level. The innovative FasTCAR platform accelerates cell production, ensuring high margins and financial support from a pharmaceutical behemoth for the rapid market launch of drugs.

GRCL (Gracell Biotechnologies) riwayat Bathi resik saben siji saham sajrone rolas wulan pungkasan saka 04.07.2022 nganti 03.03.2024

Gracell Bio - rincian analitis lan metrik utama (GRCL)

Analisis umum perusahaan:Gracell Biotechnologies (GRCL)
Produk seri Gracell

Establishing a long-term position requires an assessment of the risk of capital freezing during market downturns. The strong pricing power of Gracell Biotechnologies (GRCL), driven by its rapid CAR-T cell production method, creates a foundation for revenue growth. The 12-month net income per share trend for Gracell Biotechnologies (GRCL) reflects the final financial result distributed across the total volume of issuance. This indicator compares the actual supply of securities with the real demand for a share of profits. The stability of this metric confirms the operational resilience of the business.